Debiopharm and Cenix Partner on Preclinical Services
Preclinical contract research firm Cenix BioScience has signed a research agreement with Swiss-based biopharma company Debiopharm to support ongoing efforts to develop novel therapeutic drug candidates by identifying predictive biomarkers.
“Cenix offers a unique cell high throughput RNAi screening technology, as a CRO” said Debiopharm spokesperson Béatrice Hirt to Outsourcing-Pharma.com.
Using the Definiens XD image analysis platform, Cenix will establish multi-parametric microscopy-based readouts in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug’s therapeutic effects.
In a press release, Cenix’s CEO/CSO Dr. Christophe Echeverri said: “We are very excited to launch this new relationship with Debiopharm, extending their repertoire with what we consider to be some of the most strategically powerful cell-based screening paradigms developed to date.”
When asked, Debiopharm declined to give financial details of the collaboration.
